Get the Stockscreener App
1.95
3.17%
0.06
Pre-market:
1.96
0.01
+0.51%
Celularity Inc stock is traded at $1.95, with a volume of 16,423.
It is up +3.17% in the last 24 hours and down -5.80% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$1.89
Open:
$1.92
24h Volume:
16,423
Relative Volume:
0.12
Market Cap:
$52.05M
Revenue:
$48.20M
Net Income/Loss:
$-35.05M
P/E Ratio:
-1.2442
EPS:
-1.5673
Net Cash Flow:
$-13.02M
1W Performance:
-5.80%
1M Performance:
-5.80%
6M Performance:
+30.87%
1Y Performance:
+41.30%
1-Day Range:
$1.88
$1.96
1-Week Range:
$1.85
$2.10
52-Week Range:
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.95 | 50.45M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Strategies to average down on Celularity Inc. Equity WarrantInflation Watch & Technical Pattern Alert System - newser.com
Backtesting results for Celularity Inc. trading strategiesJuly 2025 Setups & Safe Capital Allocation Plans - newser.com
Statistical indicators supporting Celularity Inc.’s strengthWeekly Trend Recap & Low Risk Profit Maximizing Plans - newser.com
Can Celularity Inc. Equity Warrant stock beat market expectations this quarterJuly 2025 Big Picture & Safe Capital Growth Trade Ideas - newser.com
How to interpret RSI for Celularity Inc. Equity Warrant stock2025 Support & Resistance & Safe Entry Trade Signal Reports - newser.com
Why Celularity Inc. stock is a value investor pickJuly 2025 Setups & Expert-Curated Trade Recommendations - newser.com
Is Celularity Inc. Equity Warrant stock entering bullish territoryJuly 2025 Analyst Calls & Community Trade Idea Sharing Platform - newser.com
Historical volatility pattern of Celularity Inc. visualizedTrade Signal Summary & Consistent Profit Trade Alerts - newser.com
Chart based analysis of Celularity Inc. Equity Warrant trendsTrade Ideas & Safe Swing Trade Setup Alerts - newser.com
What analysts say about Celularity Inc stockPrice Volatility Patterns & Subscribe for Free Weekly Winners - earlytimes.in
What technical models suggest about Celularity Inc. Equity Warrant’s comeback2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Detecting support and resistance levels for Celularity Inc. Equity WarrantMarket Trend Report & AI Optimized Trading Strategy Guides - newser.com
Is Celularity Inc. stock a safe investment in uncertain marketsWeekly Trade Recap & Free Low Drawdown Momentum Trade Ideas - newser.com
Can Celularity Inc. Equity Warrant stock sustain market leadershipJuly 2025 Price Swings & Verified Momentum Stock Watchlist - newser.com
Quantitative breakdown of Celularity Inc. Equity Warrant recent move2025 Buyback Activity & Free Safe Capital Growth Stock Tips - newser.com
What does recent volatility data suggest for Celularity Inc.Trade Exit Report & Safe Capital Growth Tips - newser.com
Applying big data sentiment scoring on Celularity Inc. Equity WarrantMarket Activity Recap & Entry Point Confirmation Signals - newser.com
Why Celularity Inc. Equity Warrant stock remains on buy listsDip Buying & Risk Controlled Stock Alerts - newser.com
Published on: 2025-11-02 01:15:33 - newser.com
Is Celularity Inc. Equity Warrant stock supported by strong cash flowsJuly 2025 PostEarnings & Precise Buy Zone Identification - newser.com
How Celularity Inc. stock performs during Fed tightening cyclesWeekly Gains Summary & Consistent Profit Focused Trading Strategies - newser.com
Analyzing Celularity Inc. with multi timeframe chartsJuly 2025 Review & Daily Chart Pattern Signals - newser.com
Celularity Inc. Equity Warrant stock momentum explainedWeekly Profit Recap & Verified Trade Idea Suggestions - newser.com
Automated trading signals detected on Celularity Inc.2025 Macro Impact & Daily Volume Surge Signals - newser.com
Has Celularity Inc. Equity Warrant formed a bullish divergence2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com
How to escape a deep drawdown in Celularity Inc. Equity WarrantJuly 2025 Volume & Reliable Price Breakout Alerts - newser.com
Candlestick signals on Celularity Inc. stock todayGDP Growth & Safe Capital Growth Tips - newser.com
Why Celularity Inc. stock remains a top recommendationJuly 2025 Recap & Expert Approved Momentum Trade Ideas - newser.com
How to recover losses in Celularity Inc. Equity Warrant stockJuly 2025 Retail & Free High Return Stock Watch Alerts - newser.com
Will Celularity Inc. Equity Warrant stock benefit from infrastructure spendingJuly 2025 Institutional & Growth Focused Entry Reports - newser.com
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):